S*BIO sees space for its JAK inhibitor despite ruxolitinib approval
This article was originally published in Scrip
S*BIO remains confident over the prospects for its lead oral JAK inhibitor pacritinib, despite the recent first approval in the US of a competing molecule in the same space, Incyte's Jakafi (ruxolitinib), for the treatment of myelofibrosis (MF).
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.